BRL49653C

· GlaxoSmithKline

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BRL49653C, covering 2016-10-28 to 2022-11-18. Get the full timeline:

Most recent: Clinical Trial Update: BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- [Phase 3]